A61K 40/4264
From embryonic or fetal origin
Official title: {from embryonic or fetal origin}
A61K40/4264 (From embryonic or fetal origin) appears on 136 US grants and 271 published applications in this corpus.
Search patents in A61K- Granted patents
- 136
- Published applications
- 271
- Assignees
- 161
- Inventors
- 498
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 1 |
| 2002 | 2 | 1 |
| 2003 | 2 | 4 |
| 2004 | 0 | 7 |
| 2005 | 2 | 6 |
| 2006 | 2 | 1 |
| 2007 | 1 | 4 |
| 2008 | 3 | 5 |
| 2009 | 0 | 3 |
| 2010 | 4 | 2 |
| 2011 | 4 | 7 |
| 2012 | 0 | 4 |
| 2013 | 1 | 4 |
| 2014 | 3 | 3 |
| 2015 | 3 | 4 |
| 2016 | 2 | 9 |
| 2017 | 4 | 7 |
| 2018 | 8 | 16 |
| 2019 | 6 | 14 |
| 2020 | 10 | 24 |
| 2021 | 8 | 29 |
| 2022 | 19 | 31 |
| 2023 | 12 | 34 |
| 2024 | 12 | 26 |
| 2025 | 14 | 13 |
| 2026 | 12 | 12 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Chimeric antigen receptor for treatment of cancer29 Sep 2026US 12,747,278 B2Industry-Academic Cooperation Foundation, Yonsei University
- Presenting cell and use thereof in cell therapy11 Aug 2026US 12,702,708 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Molecules that bind to CD66e polypeptides11 Aug 2026US 12,703,760 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- NR4A-deficient cells expressing c-Jun and uses thereof14 Jul 2026US 12,679,879 B2Lyell Immunopharma, Inc.
- Nant cancer vaccine16 Jun 2026US 12,653,874 B2ImmunityBio, Inc.
- Chimeric Antigen Receptor Therapies for Treating Solid Tumors16 Jul 2026US 2026/0199471 A1Lentigen Technology, Inc.
- Recombinant promoter system specifically inducing high level of gene expression after t cell activation9 Jul 2026US 2026/0191906 A1Xuzhou Medical University
- Compositions and methods for treating ceacam positive cancers2 Jul 2026US 2026/0184763 A1A2 Biotherapeutics, Inc.
- Methods and compositions for cell-surface co-localization of chimeric proteins18 Jun 2026US 2026/0166083 A1Senti Biosciences, Inc.
- Armed chimeric receptors and methods of use thereof28 May 2026US 2026/0144818 A1Senti Biosciences, Inc.
Most cited
By later US patents
- Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule63US 6,045,802 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 2000
- HLA class I A2 tumor associated antigen peptides and vaccine compositions58US 6,602,510 B1Epimmune Inc. · 2003
- In situ immunization53US 7,763,243 B2Roger Williams Medical Center · 2010
- Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule52US 6,548,068 B1The United States of America, as represented by the Secretary, Department of Health and Human Services · 2003
- Noninvasive genetic immunization, expression products therefrom and uses thereof50US 6,348,450 B1The UAB Research Foundation · 2002